Optimization Of Tissue Targeting Properties Of Macitentan, A New Dual Endothelin Receptor Antagonist, Improves Its Efficacy In A Rat Model Of Pulmonary Fibrosis Associated With Pulmonary Arterial Hypertension

被引：0
|
作者：
Iglarz, M.
Landskroner, K.
Rey, M.
Wanner, D.
Hess, P.
Clozel, M.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6445
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimization of tissue targeting properties of macitentan, a new endothelin receptor antagonist, improves its efficacy in a model of pulmonary fibrosis associated with pulmonary arterial hypertension
    Iglarz, M.
    Landskroner, K.
    Rey, M.
    Wanner, D.
    Hess, P.
    Clozel, M.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 434 - 434
  • [2] Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis
    Raja, Shahzad G.
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (09) : 1066 - 1073
  • [3] Treatment of pulmonary arterial hypertension with macitentan, dual endothelin receptor antagonist
    Bichara, Valentina M.
    Bevacqua, Raul J.
    [J]. INSUFICIENCIA CARDIACA, 2019, 14 (03) : 119 - 128
  • [4] The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
    Steriade, Alexandru
    Seferian, Andrei
    Jais, Xavier
    Savale, Laurent
    Jutant, Etienne-Marie
    Parent, Florence
    Sitbon, Olivier
    Humbert, Marc
    Simonneau, Gerald
    Montani, David
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2014, 8 (03) : 84 - 92
  • [5] The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
    Avdeev, S. N.
    [J]. TERAPEVTICHESKII ARKHIV, 2016, 88 (07): : 89 - 97
  • [6] Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
    Belge, Catharina
    Delcroix, Marion
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [7] Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension
    Schweintzger, Sabrina
    Koestenberger, Martin
    Schlagenhauf, Axel
    Grangl, Gernot
    Burmas, Ante
    Kurath-Koller, Stefan
    Pocivalnik, Mirjam
    Sallmon, Hannes
    Baumgartner, Daniela
    Hansmann, Georg
    Gamillscheg, Andreas
    [J]. CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (05) : 1675 - 1685
  • [8] Novel Dual Endothelin Receptor Antagonist Macitentan Reverses Severe Pulmonary Arterial Hypertension in Rats
    Kunita-Takanezawa, Mutsumi
    Abe, Kohtaro
    Hirooka, Yoshitaka
    Kuwabara, Yukimitsu
    Hirano, Katsuya
    Oka, Masahiko
    Sunagawa, Kenji
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (05) : 473 - 480
  • [9] Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension
    Tahara, Nobuhiro
    Dobashi, Hiroaki
    Fukuda, Keiichi
    Funauchi, Masanori
    Hatano, Masaru
    Ikeda, Satoshi
    Joho, Shuji
    Kihara, Yasuki
    Kimura, Takeshi
    Kondo, Takahisa
    Matsushita, Masakazu
    Minamino, Tohru
    Nakanishi, Norifumi
    Ozaki, Yukio
    Saji, Tsutomu
    Sakai, Satoshi
    Tanabe, Nobuhiro
    Watanabe, Hiroshi
    Yamada, Hidehiro
    Yoshioka, Koichiro
    Sasayama, Shigetake
    [J]. CIRCULATION JOURNAL, 2016, 80 (06) : 1478 - 1483
  • [10] Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Sidharta, Patricia N.
    Kraehenbuehl, Stephan
    Dingemanse, Jasper
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (03) : 437 - 449
12345